Skip to content

Author

A. Singh

We have 4 of 30 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Nov 2026

Prognostic value of lymph node ratio beyond extranodal extension in node-positive oral cavity squamous cell carcinoma.

PURPOSE Extranodal extension (ENE) is a key determinant of adjuvant therapy in node-positive oral cavity squamous cell carcinoma (OCSCC). However, conventional nodal staging may not fully capture the quantitative burden of nodal disease. We evaluated whether lymph node ratio (LNR) provides additional prognostic value b...

Anuj Kumar, S. Ghosh-Laskar, Prashasti Sharma et al. · 0 citations
Open access Oct 2026

Metastasis-directed therapy in addition to definitive locoregional radiotherapy for De novo metastatic nasopharyngeal carcinoma: a retrospective cohort study

Background De novo metastatic nasopharyngeal carcinoma (mNPC) carries a poor prognosis with systemic therapy alone. Locoregional radiotherapy (LRRT) improves survival in chemotherapy-responsive patients, but the incremental role of metastasis-directed therapy (MDT) remains undefined. Methods This retrospective cohort i...

S. Ghosh-Laskar, Anuj Kumar, R. Malhotra et al. · 0 citations
Review Open access Sep 2026

Imaging-Based Tumor Margin Patterns and Primary Tumor Categories and Their Association with Adverse Histopathological Features in Oral Tongue Squamous Cell Carcinoma

Background: This retrospective study introduces imaging inner tumor margin patterns (iITMP) and evaluates their correlation with pathological Worst pattern of invasion (WPOI) in oral tongue squamous cell carcinoma (OTSCC). Associations of iITMP with pathological primary tumor category (pT), histologic grade, perineural...

N. Chakrabarty, Tapish Dadlani, A. Mahajan et al. · 0 citations
Open access Sep 2026

MRI radiomics-based predictive modeling for risk stratification and prognostication in oral tongue carcinoma

By identifying low-risk patients within the NCCN high-risk group and high-risk patients within the NCCN low + intermediate-risk group for recurrence, these models may support treatment de-escalation and escalation, respectively, pending prospective multicenter validation.

N. Chakrabarty, S. Rane, U. Sherkhane et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.